White House Bats Down Speculation that Trump Got Access to Eli Lilly Obesity Drug for ‘Compassionate Use’
White House officials say the application was not for Trump after STAT reported that one 79-year-old gained rare access to the unapproved obesity drug.
- On Tuesday, health news site STAT reported that an unidentified 79-year-old man secured 'compassionate use' access to Eli Lilly's experimental obesity drug retatrutide, prompting speculation the patient was President Donald Trump—a claim the White House aggressively denied.
- Retatrutide, a triple hormone receptor agonist currently in Phase 3 clinical trials, was requested through the Food and Drug Administration's 'compassionate use' program, which allows patients with serious, life-threatening conditions to access experimental treatments before FDA approval.
- A senior National Institutes of Health clinician requested the medication in April for a 79-year-old patient diagnosed with refractory obesity, obstructive sleep apnea, and pulmonary hypertension; the request drew interest from top officials, suggesting the recipient was well-connected.
- White House spokesperson Kush Desai lashed out at STAT reporter Lizzy Lawrence on social media, calling the speculation 'baseless' and labeling Lawrence an 'unserious gossip columnist' while insisting 'this application was not for the President.'
- Bioethics experts and clinicians told STAT that individual compassionate use access for a weight-loss drug is highly unusual, raising questions about why an undisclosed person received special treatment when obesity affects millions of Americans without such alternatives.
25 Articles
25 Articles
Did Ailing Trump Secretly Obtain Powerful Obesity Drug Under 'Compassionate Use'?
The health-focused news outlet STAT on Tuesday published a bombshell report that suggests President Donald Trump may have used his position of power to obtain a powerful new obesity drug not yet approved by the Food and Drug Administration.According to the report, the FDA in April allowed one 79-year-old man to obtain Eli Lilly’s retatrutide, an experimental weight-loss drug, through a “compassionate use” waiver. That kind of waiver, according t…
White House shuts down claims Trump is taking experimental weight-loss drug
The White House has refuted a claim that President Donald Trump was given access to a limited-use miracle drug. On Tuesday, Stat News ran a bombshell report about a “powerful new drug” made by Eli Lilly called retatrutide. The drug “has demonstrated bariatric-surgery levels of weight loss,” according to the outlet. The report further revealed that Eli Lilly and the Food and Drug Administration (FDA) have thus far only allowed a single person to …
White House shuts down claims Trump is taking experimental weight-loss drug · American Wire News
The White House has refuted a claim that President Donald Trump was given access to a limited-use miracle drug. On Tuesday, Stat News ran a bombshell report about a “powerful new drug” made by Eli Lilly called retatrutide. The drug “has demonstrated bariatric-surgery levels of weight loss,” according to the outlet. The report further revealed that Eli Lilly and the Food and Drug Administration (FDA) have thus far only allowed a single person to …
Coverage Details
Bias Distribution
- 42% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
